{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:25:40Z","timestamp":1760909140878,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T00:00:00Z","timestamp":1525305600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"IGA NT","award":["12205-5\/201"],"award-info":[{"award-number":["12205-5\/201"]}]},{"name":"RVO VFN","award":["64165"],"award-info":[{"award-number":["64165"]}]},{"name":"Progres","award":["Q25\/LF1"],"award-info":[{"award-number":["Q25\/LF1"]}]},{"name":"SVV","award":["260 263"],"award-info":[{"award-number":["260 263"]}]},{"DOI":"10.13039\/501100008530","name":"ERDF","doi-asserted-by":"crossref","award":["BIOCEV CZ.1.05\/1.1.00\/02.0109"],"award-info":[{"award-number":["BIOCEV CZ.1.05\/1.1.00\/02.0109"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]},{"name":"MEYS","award":["LQ1604 NPU II"],"award-info":[{"award-number":["LQ1604 NPU II"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s40291-018-0333-0","type":"journal-article","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T07:48:04Z","timestamp":1525333684000},"page":"381-390","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Gene Expression Analysis of Immunomagnetically Enriched Circulating Tumor Cell Fraction in Castration-Resistant Prostate Cancer"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7165-4410","authenticated-orcid":false,"given":"Mark\u00e9ta","family":"\u0160kere\u0148ov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9962-5312","authenticated-orcid":false,"given":"Veronika","family":"Mikulov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2332-3174","authenticated-orcid":false,"given":"Otakar","family":"\u010capoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"\u0160vec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katar\u00edna","family":"Kolo\u0161tov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5313-9629","authenticated-orcid":false,"given":"Viktor","family":"Soukup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Honov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1\u0161","family":"Hanu\u0161","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8518-6972","authenticated-orcid":false,"given":"Tom\u00e1\u0161","family":"Zima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,3]]},"reference":[{"key":"333_CR1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424\u201333.","journal-title":"N Engl J Med"},{"key":"333_CR2","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1093\/annonc\/mdt194","volume":"24","author":"A Bahl","year":"2013","unstructured":"Bahl A, Oudard S, Tombal B, Ozg\u00fcroglu M, Hansen S, Kocak I, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol. 2013;24:2402\u20138.","journal-title":"Ann Oncol"},{"key":"333_CR3","doi-asserted-by":"publisher","first-page":"e1107698","DOI":"10.1080\/2162402X.2015.1107698","volume":"5","author":"JL Gulley","year":"2016","unstructured":"Gulley JL, Mulders P, Albers P, Banchereau J, Bolla M, Pantel K, et al. Perspectives on sipuleucel-T: its role in the prostate cancer treatment paradigm. Oncoimmunology. 2016;5:e1107698.","journal-title":"Oncoimmunology."},{"key":"333_CR4","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138\u201348.","journal-title":"N Engl J Med"},{"key":"333_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.eururo.2011.11.009","volume":"61","author":"AJ Armstrong","year":"2012","unstructured":"Armstrong AJ, Eisenberger MA, Halabi S, Oudard S, Nanus DM, Petrylak DP, et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol. 2012;61:549\u201359.","journal-title":"Eur Urol"},{"key":"333_CR6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/ng.2650","volume":"45","author":"A Lunardi","year":"2013","unstructured":"Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, et al. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet. 2013;45:747\u201355.","journal-title":"Nat Genet"},{"key":"333_CR7","doi-asserted-by":"publisher","first-page":"R103","DOI":"10.1530\/ERC-10-0343","volume":"18","author":"KL Mahon","year":"2011","unstructured":"Mahon KL, Henshall SM, Sutherland RL, Horvath LG. Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocr Relat Cancer. 2011;18:R103\u201323.","journal-title":"Endocr Relat Cancer"},{"key":"333_CR8","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028\u201338.","journal-title":"N Engl J Med"},{"key":"333_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nm972","volume":"10","author":"CD Chen","year":"2004","unstructured":"Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33\u20139.","journal-title":"Nat Med"},{"key":"333_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13045-017-0429-8","volume":"15","author":"J-F Chen","year":"2017","unstructured":"Chen J-F, Lu Y-T, Cheng S, Tseng H-R, Figlin RA, Posadas EM. Circulating tumor cells in prostate cancer: beyond enumeration. Clin Adv Hematol Oncol. 2017;15:63\u201373.","journal-title":"Clin Adv Hematol Oncol."},{"key":"333_CR11","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/pros.22625","volume":"73","author":"C-L Chen","year":"2013","unstructured":"Chen C-L, Mahalingam D, Osmulski P, Jadhav RR, Wang C-M, Leach RJ, et al. Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer. Prostate. 2013;73:813\u201326.","journal-title":"Prostate"},{"key":"333_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ctrv.2016.04.001","volume":"46","author":"W Onstenk","year":"2016","unstructured":"Onstenk W, de Klaver W, de Wit R, Lolkema M, Foekens J, Sleijfer S. The use of circulating tumor cells in guiding treatment decisions for patients with metastatic castration-resistant prostate cancer. Cancer Treat Rev. 2016;46:42\u201350.","journal-title":"Cancer Treat Rev"},{"key":"333_CR13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40291-014-0101-8","volume":"18","author":"G Galletti","year":"2014","unstructured":"Galletti G, Portella L, Tagawa ST, Kirby BJ, Giannakakou P, Nanus DM. Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential. Mol Diagn Ther. 2014;18:389\u2013402.","journal-title":"Mol Diagn Ther."},{"key":"333_CR14","first-page":"2019","volume":"36","author":"O \u010capoun","year":"2016","unstructured":"\u010capoun O, Mikulov\u00e1 V, Jan\u010d\u00edkov\u00e1 M, Honov\u00e1 H, Kolo\u0161tov\u00e1 K, Sobotka R, et al. Prognosis of castration-resistant prostate cancer patients\u2014use of the AdnaTest\u00ae system for detection of circulating tumor cells. Anticancer Res. 2016;36:2019\u201326.","journal-title":"Anticancer Res"},{"key":"333_CR15","first-page":"3507","volume":"32","author":"T Todenh\u00f6fer","year":"2012","unstructured":"Todenh\u00f6fer T, Hennenlotter J, Feyerabend S, Aufderklamm S, Mischinger J, K\u00fchs U, et al. Preliminary experience on the use of the Adnatest\u00ae system for detection of circulating tumor cells in prostate cancer patients. Anticancer Res. 2012;32:3507\u201313.","journal-title":"Anticancer Res"},{"key":"333_CR16","doi-asserted-by":"publisher","first-page":"e1102827","DOI":"10.1080\/2162402X.2015.1102827","volume":"5","author":"M Hensler","year":"2016","unstructured":"Hensler M, Van\u010durov\u00e1 I, Becht E, Palata O, Strnad P, Tesa\u0159ov\u00e1 P, et al. Gene expression profiling of circulating tumor cells and peripheral blood mononuclear cells from breast cancer patients. Oncoimmunology. 2016;5:e1102827.","journal-title":"Oncoimmunology."},{"key":"333_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.11613\/BM.2016.011","volume":"26","author":"M \u0160kere\u0148ov\u00e1","year":"2016","unstructured":"\u0160kere\u0148ov\u00e1 M, Mikulov\u00e1 V, \u010capoun O, Zima T. The characterization of four gene expression analysis in circulating tumor cells made by Multiplex-PCR from the AdnaTest kit on the lab-on-a-chip Agilent DNA 1000 platform. Biochem Medica. 2016;26:103\u201313.","journal-title":"Biochem Medica."},{"key":"333_CR18","doi-asserted-by":"crossref","unstructured":"Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of realtime quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3(7):RESEARCH0034","DOI":"10.1186\/gb-2002-3-7-research0034"},{"issue":"15","key":"333_CR19","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.1158\/0008-5472.CAN-04-0496","volume":"64","author":"CL Andersen","year":"2004","unstructured":"Andersen CL, Jensen JL, \u00d8rntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004;64(15):5245\u201350.","journal-title":"Cancer Res."},{"key":"333_CR20","doi-asserted-by":"publisher","first-page":"426218","DOI":"10.1155\/2010\/426218","volume":"2010","author":"AL Allan","year":"2010","unstructured":"Allan AL, Keeney M. Circulating tumor cell analysis: technical and statistical considerations for application to the clinic. J Oncol. 2010;2010:426218.","journal-title":"J Oncol."},{"key":"333_CR21","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s10549-008-0290-0","volume":"118","author":"AM Sieuwerts","year":"2009","unstructured":"Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, Mostert B, Martens JWM, et al. Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res Treat. 2009;118:455\u201368.","journal-title":"Breast Cancer Res Treat"},{"key":"333_CR22","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1373\/clinchem.2010.143297","volume":"56","author":"Y Jiang","year":"2010","unstructured":"Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem. 2010;56:1492\u20135.","journal-title":"Clin Chem"},{"key":"333_CR23","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1093\/annonc\/mdv282","volume":"26","author":"M Nakazawa","year":"2015","unstructured":"Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, Eisenberger MA, et al. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Ann Oncol. 2015;26:1859\u201365.","journal-title":"Ann Oncol"},{"key":"333_CR24","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1093\/annonc\/mdv311","volume":"26","author":"C Sprenger","year":"2015","unstructured":"Sprenger C, Uo T, Plymate S. Androgen receptor splice variant V7 (AR-V7) in circulating tumor cells: a coming of age for AR splice variants? Ann Oncol. 2015;26:1805\u20137.","journal-title":"Ann Oncol"},{"key":"333_CR25","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.eururo.2015.07.007","volume":"68","author":"W Onstenk","year":"2015","unstructured":"Onstenk W, Sieuwerts AM, Kraan J, Van M, Nieuweboer AJM, Mathijssen RHJ, et al. Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells. Eur Urol. 2015;68:939\u201345.","journal-title":"Eur Urol"},{"key":"333_CR26","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1002\/pros.22839","volume":"74","author":"S Dijkstra","year":"2014","unstructured":"Dijkstra S, Leyten GHJM, Jannink SA, de Jong H, Mulders PFA, van Oort IM, et al. KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment. Prostate. 2014;74:1222\u201330.","journal-title":"Prostate"},{"key":"333_CR27","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1039\/C3IB40264A","volume":"6","author":"X Yao","year":"2014","unstructured":"Yao X, Choudhury AD, Yamanaka YJ, Adalsteinsson VA, Gierahn TM, Williamson CA, et al. Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits. Integr Biol. 2014;6:388\u201398.","journal-title":"Integr Biol."},{"key":"333_CR28","doi-asserted-by":"publisher","first-page":"34930","DOI":"10.18632\/oncotarget.9004","volume":"7","author":"TM Gorges","year":"2016","unstructured":"Gorges TM, Riethdorf S, von Ahsen O, Nasta\u0142 YP, R\u00f6ck K, Boede M, et al. Heterogeneous PSMA expression on circulating tumor cells: a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer. Oncotarget. 2016;7:34930\u201341.","journal-title":"Oncotarget."},{"key":"333_CR29","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1158\/1078-0432.CCR-15-2309","volume":"22","author":"S Gao","year":"2016","unstructured":"Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, et al. ErbB2 signaling increases androgen receptor expression in abiraterone-resistant prostate cancer. Clin Cancer Res. 2016;22:3672\u201382.","journal-title":"Clin Cancer Res"},{"key":"333_CR30","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18632\/genesandcancer.40","volume":"6","author":"A Shvartsur","year":"2015","unstructured":"Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications. Genes Cancer. 2015;6:84\u2013105.","journal-title":"Genes Cancer."},{"key":"333_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/annonc\/mdn544","volume":"20","author":"D Olmos","year":"2009","unstructured":"Olmos D, Arkenau H-T, Ang JE, Ledaki I, Attard G, Carden CP, et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol. 2009;20:27\u201333.","journal-title":"Ann Oncol"},{"key":"333_CR32","doi-asserted-by":"publisher","first-page":"110.e1","DOI":"10.1016\/j.urolonc.2014.09.002","volume":"33","author":"RL Bitting","year":"2015","unstructured":"Bitting RL, Healy P, Halabi S, George DJ, Goodin M, Armstrong AJ. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer. Urol Oncol. 2015;33:110.e1\u20139.","journal-title":"Urol Oncol."}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40291-018-0333-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-018-0333-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-018-0333-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T13:20:42Z","timestamp":1604236842000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40291-018-0333-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["333"],"URL":"https:\/\/doi.org\/10.1007\/s40291-018-0333-0","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"type":"print","value":"1177-1062"},{"type":"electronic","value":"1179-2000"}],"subject":[],"published":{"date-parts":[[2018,5,3]]},"assertion":[{"value":"3 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was supported by the Ministry of Health, Czech Republic, IGA NT 12205-5\/201; institutional support of the General University Hospital RVO VFN 64165 and Progres Q25\/LF1; research support of the First Faculty of Medicine SVV 260 263; BIOCEV CZ.1.05\/1.1.00\/02.0109 from the European Regional Development Fund (ERDF); and LQ1604 NPU II provided by Ministry of Education, Youth and Sports (MEYS).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mark\u00e9ta \u0160kere\u0148ov\u00e1, Veronika Mikulov\u00e1, Otakar \u010capoun, David \u0160vec, Katar\u00edna Kolo\u0161tov\u00e1, Viktor Soukup, Hana Honov\u00e1, Tom\u00e1\u0161 Hanu\u0161, and Tom\u00e1\u0161 Zima state that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}